AUTL - Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress | Benzinga

LONDON, May 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 13-16, 2024.

Oral presentation:

1. Title: obecabtagene autoleucel in adult relapsed/refractory B Cell acute lymphoblastic leukemia: Survival and potential impact of CAR-T cell persistence and stem cell transplantation in the FELIX study
   Session Title: s419 Acute lymphoblastic leukemia - Clinical 1: Immunotherapy: antibodies and CAR-T cells
   Session date and time: Friday, June 14 from 14:45 - 16:00 CEST
   Session room: N104
   Final Abstract Code: S114
   Presenting Author: Dr. Claire Roddie

Poster presentations:

1. Title: obecabtagene autoleucel (obe-cel, AUTO1) for relapsed/refractory adult B-Cell acute lymphoblastic leukemia (R/R B-ALL): The impact of inotuzumab-containing bridging therapy on treatment outcomes
   Session Title: Poster session
   Session date and time: Friday, June 14 from 18:00 - 19:00 CEST
   Final Abstract Code: P418
   Presenting Author: Dr. Jae H. Park
   
   
2. Title: Droplet digital PCR and flow ...

Full story available on Benzinga.com